Physician profile
Ann E James
NPI 1285692921
$1,401.33
in general payments reported to CMS, 2019-2025
27 companies · $205 in 2025
The $205 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.08 · 2022: $324 · 2023: $527 · 2024: $271 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450.21 | 2021-2025 | |
| Glaxosmithkline, LLC. | $121.05 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Pfizer INC. | $108.07 | 2023-2024 | |
| Novo Nordisk INC | $75.96 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $54.36 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.53 | 2023-2024 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $45.27 | 2022-2025 | |
| Lundbeck LLC | $42.09 | 2023-2024 | Abilify Asimtufii, Vyepti |
| Ironshore Pharmaceuticals INC. | $39.95 | 2022-2023 | Jornay Pm |
| Merck Sharp & Dohme LLC | $38.54 | 2021-2025 | Gardasil 9, Enflonsia, Capvaxive |
| Astellas Pharma US INC | $37.44 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $33.67 | 2023-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $31.93 | 2021-2024 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $31.79 | 2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $31.56 | 2022-2023 | Qelbree |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $24.92 | 2022 | |
| Corium, LLC | $20.41 | 2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.32 | 2022 | |
| Axsome Therapeutics, INC. | $18.88 | 2024 | Auvelity |
| Exact Sciences Corporation | $18.63 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $17.76 | 2022 | |
| Amgen INC. | $17.33 | 2022 | |
| Insulet Corporation | $16.66 | 2024 | Omnipod |
| Idorsia Pharmaceuticals US INC | $16.39 | 2023 | Quviviq |
| Adlon Therapeutics L.P. | $13.17 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.29 | 2022 | |
| Horizon Therapeutics Plc | $11.15 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann James listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.